The discoveric bio group currently comprises three separate companies dedicated to the development of novel therapeutics for the treatment of Alzheimer’s Disease, Neuroinflammation and Antimicrobial Resistant infections. We employ bi- and multi-specific, truly natural IgG antibody technologies.
- discoveric bio alpha Ltd. – Alzheimer’s Disease
- discoveric bio beta Ltd. – Antimicrobial Resistance
- discoveric bio gamma Ltd. – Neuroinflammation
Each of these companies is working independently on one or more antibody therapeutic projects.
